Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD489 (Vyvanse) for Executive Function in Adults with ADHD
NCT01101022Phase 4Completed
- Sponsor
- Takeda
- Start
- May 2010
- Primary completion
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing SPD489 with Placebo (2 arms). Primary endpoint: Change From Baseline in Subject-reported Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score at 10 weeks. Started May 2010; status: completed.
02
Drugs
lisdexamfetamine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT01101022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01101022.